Supernus Pharmaceuticals (SUPN) PT Raised to $63 at Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska raised the price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $63.00 (from $46.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
